Oral AT2 Receptor Agonist Therapy for Restoring IPF Lung Function

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no curative treatments for idiopathic pulmonary fibrosis (IPF), and existing treatments like nintedanib and pirfenidone only slow the progression of the disease while causing significant side effects, with lung transplantation being the only effective but risky option.

Innovation Solution

The use of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), a selective angiotensin II type 2 receptor agonist, administered orally, to improve and potentially reverse lung function in IPF patients.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments like nintedanib and pirfenidone are used to slow IPF progression, then disease progression is slowed, but significant side effects occur

Engineering Contradiction:

Improvedisease progression controlVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter from antifibrotic inhibition (nintedanib, pirfenidone) to angiotensin II type 2 receptor agonism (C21), representing a fundamental mechanism change. This parameter change in therapeutic approach achieves disease progression control while minimizing side effects, as C21 targets a different pathway (AT2 receptor) that does not carry the same adverse effect profile as existing antifibrotics

Inventive Principle:

Principle #35Parameter changes

2Reliability

If lung transplantation is performed to effectively treat IPF, then lung function is restored, but significant surgical risks and complications occur

Engineering Contradiction:

Improvelung function restorationVSAvoidsurgical risks

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical/surgical intervention of lung transplantation with a pharmacological approach using C21. Instead of physically replacing the damaged organ through surgery, the invention uses a drug that activates AT2 receptors to promote tissue repair and regeneration, thereby restoring lung function through biochemical mechanisms rather than mechanical replacement, thus eliminating surgical risks

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Object-affected harmful factors

If no treatment is given for IPF, then no side effects occur, but lung function continuously deteriorates

Engineering Contradiction:

Improveside effectsVSAvoidlung function maintenance

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent introduces C21 as an intermediary substance that mediates between the body's existing AT2 receptors and the pathological fibrotic process. C21 acts as a pharmacological mediator that binds to and activates AT2 receptors, triggering downstream signaling pathways that promote anti-fibrotic effects and tissue repair, thereby maintaining lung function without direct toxic exposure

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260069572A1Treatment of idiopathic pulmonary fibrosis

Publication Date: 2026.03.12 VICORE PHARMA AB

AI summary

According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.